Skip to main content
. 2024 Mar 9;14:5778. doi: 10.1038/s41598-024-56543-y

Table 3.

Drug treatment at 52 weeks after IN discontinuation (patients who relapse after IN discontinuation, n = 50).

Treatment Number of patients
Post-relapse treatment at 52 weeks after IN discontinuation
 IN 12
 Anti-TNF-α inhibitor 2
 Anti-α4β7 integrin inhibitor 5
 JAK inhibitor 2
 Anti-IL12p19 inhibitor 2
 Anti-IL12/23p40 inhibitor 1
 Increase 5ASA 16
 Azathioprine/6-mercaptopurine 10